Researchers have demonstrated that a single alteration of a key gene can reduce heart-clogging cholesterol levels by approximately 50% over a year without any adverse effects, reports BritPanorama.
The findings, published in a pilot study in The New England Journal of Medicine in November 2025, highlighted a positive outcome in four participants who received the highest dose of the experimental treatment. While the initial study involved just 15 patients with dangerously high cholesterol unresponsive to conventional medication, it aimed to assess the safety of varying doses of a gene-editing infusion utilizing CRISPR-Cas9 technology.
Dr. Steven Nissen, chief academic officer at Cleveland Clinic, expressed surprise at the results. “If you’d asked me 15 years ago if we could have done something like this, I would have thought you were crazy,” he remarked.
The updated analysis posed a crucial question: Does the intervention provide lasting results? Lead author Dr. Luke Laffin, a preventive cardiologist at the same institute, affirmed that, based on new data, the reductions in LDL cholesterol and triglycerides observed shortly after treatment appear to be durable and safe over the long term.
Low-density lipoprotein, or LDL, recognized widely as “bad” cholesterol, significantly contributes to the risk of heart disease, which remains the leading cause of death globally. Dr. Ann Marie Navar, who was not involved in the study, indicated that if subsequent larger clinical trials substantiate these results, the new procedure could revolutionize treatment for young individuals with severe cholesterol issues.
The gene-editing approach was inspired by a natural mutation in the ANGPTL3 gene, responsible for regulating LDL and triglyceride levels. Individuals with this mutation typically exhibit both extremely low cholesterol and triglyceride levels throughout their lives, along with a significantly lowered risk of heart disease.
Overall, the clinical trial administered various doses of the CRISPR-based drug to different groups, revealing that the highest dose resulted in the most significant reductions in cholesterol levels—nearly 50% for LDL and 55% for triglycerides measured two months after treatment. The longevity of these results highlights the potential of gene therapy to offer an alternative to conventional daily medications.
While the initial treatment showed minimal side effects, including some localized irritation and isolated incidents of more severe health concerns, Dr. Nissen remains cautious yet optimistic. He noted that the FDA has recommended ongoing monitoring of participants for a period extending to 15 years to identify any possible long-term effects.
The research team will soon begin a new clinical trial, which will include up to 40 participants receiving the highest dose of the treatment. Laffin acknowledged a remarkable public response, with many inquiring about involvement in trials, indicating a growing willingness among patients to consider genetic treatments.
The path forward remains a gradual one, as further phases of clinical trials will be necessary before the intervention could become widely adopted. Yet, the potential for a breakthrough in cholesterol management is clearly within sight.
